Gilead Sciences lenacapavir shows potential in transforming HIV clinical care
New data presented by Gilead Sciences, Inc. has highlighted the efficacy, safety, and patient tolerability of Sunlenca (lenacapavir), the first long-acting injectable HIV treatment administered ... Read More
Gilead Sciences discontinues Phase 3 ENHANCE Study on higher-risk MDS due to futility
Biopharmaceutical firm Gilead Sciences (Nasdaq: GILD) has announced the termination of its Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to a lack ... Read More
FDA approves Gilead’s Veklury for COVID-19 patients with severe renal impairment
Gilead Sciences said that the US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury (remdesivir) usage in COVID-19 ... Read More
Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More
Gilead Sciences partners with EVOQ Therapeutics on immunotherapies
American biopharma major Gilead Sciences and immunotherapy company EVOQ Therapeutics have entered into a partnership to develop and market immunotherapy products. Under the collaboration and ... Read More
Kite Pharma gets Yescarta approval in Japan for large B-cell lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for their ... Read More
Gilead Sciences gets Sunlenca FDA approval for multi-drug resistant HIV
Sunlenca FDA approval : Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Sunlenca (lenacapavir), in combination with other ... Read More
Gilead’s Kite to acquire CAR T-therapies developer Tmunity Therapeutics
Kite, an arm of Gilead Sciences, has agreed to acquire Tmunity Therapeutics, a Philadelphia-based clinical-stage biotech company focused on next-generation CAR T-therapies and technologies, for ... Read More
Arcellx, and Kite to jointly advance CART-ddBMCA for multiple myeloma
Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the former’s CART-ddBCMA, a late-stage product candidate. CART-ddBCMA, ... Read More
Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More